 |
|
|
| |
IDUs/Intervention Model Global - What is needed to control
Hepatitis C (HCV) in different epidemiological settings?
|
| |
| |
Reported by Jules Levin
EASL 2014 April 22-26 Vienna Austria
Hannah Woodalla, Natasha Martinb,a, Tim Hallettc, Graham Cookec, Matthew Hickmana, Peter Vickermana
aUniversity of Bristol, Bristol, United Kingdom, bUniversity of California San Diego, USA, cImperial College London, London, United Kingdom
EASL: THE GLOBAL AND REGIONAL BURDEN OF LIVER DISEASE, 2013: deaths due to HCV doubled from 1990 to 2013 - (04/27/15)
EASL: IDU / How should scale up of HCV antiviral treatment be prioritized? A cost-effectiveness analysis including individual and population prevention benefits - (05/15/15)
EASL: HCV Screening/treatment in UK Prisons Can be Cost-Effective - IS INCREASED HCV CASE-FINDING COMBINED WITH 8 OR 12 WEEK INTERFERON-FREE DIRECT-ACTING ANTIVIRAL TREATMENT COST EFFECTIVE IN UK PRISONS? A COST UTILITY ANALYSIS INCLUDING TREATMENT AS PREVENTION BENEFITS - (04/27/15)
100+ EASL Reports - scientific / comprehensive / independent .......
EASL: HEALTHCARE ECONOMICS / SVR Improves Health, Mortality / Early HCV Therapy Prefer - (05/14/15)
EASL - The International Liver Congress 2015 50th Annual Meeting of the European
Association for the Study of the Liver Vienna, Austria April 22-26
|
| |
|
|
|
|
|
